Events Related Topics 
MedCity News
NOVEMBER 12, 2024
The post Neurogene Gene Therapy Shows Signs of Efficacy in Small Study, But an Adverse Event Spooks Investors appeared first on MedCity News. But a late-breaking report of a serious complication in a patient who received the high dose sent shares of the biotech downward.
MedCity News
OCTOBER 3, 2024
The post First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic appeared first on MedCity News. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
DECEMBER 4, 2022
Companies who do all the right things along the path to FDA approval while simultaneously doing all the right things for a hospital Value Analysis Committee’s approval are the companies that help hospitals avoid expensive and harmful “never events.”.
MedCity News
APRIL 11, 2023
The serious adverse event reported in the early-stage study resolved quickly, but Chinook Therapeutics said it is suspected to be related to its experimental primary hyperoxaluria therapy. Meanwhile, Human Immunology Biosciences is looking ahead to Phase 3 after its rare kidney disease drug posted positive mid-stage data.
Advertisement
We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety.
MedCity News
JANUARY 30, 2025
Phase 2 data for Cargo Therapeutics CD22-targeting cell therapy show low durability and cases of a severe immune response, some that were classified as grade 4 or 5 serious adverse events. Cargo is discontinuing the study and shifting focus to a different cell therapy on track to begin Phase 1 testing in mid-2025.
Fierce Pharma
AUGUST 13, 2024
When the FDA approved Amgen’s Imdelltra in May, the T-cell engager was hailed as a breakthrough for the treatment of small cell lung cancer (SCLC) and as the first DLL3-targeting therapy of potenti | In granting an accelerated approval to Amgen's first-in-class DLL3 bispecific Imdelltra, the FDA had to work through a “large number” of missing (..)
Advertiser: ZoomInfo
However, there is also strong evidence which points to the contrary - 78% of decision-makers have taken an appointment or attended an event as a result of a cold call. In fact, less than 2% of today’s cold calls actually result in meetings, and 63% of sales professionals say it’s what they dislike most about their jobs. What’s the verdict?
Expert insights. Personalized for you.
275 
Let's personalize your content